Treatment for Head and Neck Cancer with NIMOTUZUMAB

Cuba offers the possibility to people from all over the world to access a complete therapeutic program for patients with different head and neck tumors

This therapy with the use of monoclonal antibodies, combines medical science and technology, and is also supported by the contribution of other important institutions, such as the Center for Molecular Immunology (CIM), where several therapeutic vaccines have been developed with proven efficiency in certain types of tumors.

Nimotuzumab, is a humanized monoclonal antibody for the treatment of cancer. It was developed at the Center for Molecular Immunology in Havana, Cuba. Nimotuzumab binds with the affinity of the intermediate and the high specificity with the extracellular region of EGFR (epidermal growth factor receptor). This produces a competition between the ligand and the activation of the receptor. The epidermal growth factor receptor (EGFR) is an important target in the development of cancer therapies. Combining Nimotuzumab with conventional treatments such as radiation therapy and chemotherapy has been shown to improve objective response. HR3 is obtained by genetic engineering and acts on your immune system, activating it and this in turn controls the growth of tumor cells because it competes with the proliferation factors with its receptor in the tumor cell, slowing down the growth rate of the tumor. .

This treatment is personalized and is carried out according to the needs of the patient, after being evaluated by a multidisciplinary medical team.

Details of the treatment of head and neck tumors with NIMOTUZUMAP

Hospitalization

4 nights of hospitalization in a private room (includes food and nursing care).

Attention of the hospitalized patient assistance doctor (includes visit pass).

Initial evaluation and preparation of medical history.

Queries

• Consultation with an Oncology specialist

Investigations

• Complete blood count.
• Sedimentation rate.
• Complete coagulogram.
• Glycemia.
• Creatinine
• Uric acid
• Urea
• TGO
• TGG
• GGT
• Alkaline phosphatase
• Quantitative serology (VDRL)
• Antibody test against HIV-1/2

Imaging investigations:

• Chest X-ray

Monoclonal antibody therapy and other medications:

• Vaccine NIMOTUZUMAB
• Zofran
• Sodium Chloride

In-out transportation

Medical report, conclusions and recommendations.

Requirements to be a candidate for Nimotuzumab monoclonal antibody therapy

• Having been diagnosed with epithelial tumors of the head and neck and tumors of the Central Nervous System
• Having completed the first line of cancer-specific treatment (Surgery / Radiotherapy)
• Objective response has been evaluated as stable disease, complete or partial remission, according to the established RECIST criteria, 4 weeks after completion of primary treatment and no more than 8 weeks have elapsed after completion of this treatment.
• Be over 18 years old
• Not having negative criteria from a functional point of view: complementary within normal limits of Hematological and Hemochemical figures
• Life expectancy of at least 3 months
• WHO Clinical Status 0 to 2
• If you are a female patient of childbearing age you must use adequate contraception and have a negative pregnancy test
• You must not be receiving any other monoclonal treatment